NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its quarterly earnings data on Monday, November, 4th. The company reported ($1.28) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.19) by $0.09. View Deciphera Pharmaceuticals' Earnings History.

Deciphera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Deciphera Pharmaceuticals.

13 brokers have issued 1 year target prices for Deciphera Pharmaceuticals' stock. Their forecasts range from $29.00 to $84.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $62.23 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price. View Analyst Price Targets for Deciphera Pharmaceuticals.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.

News stories about DCPH stock have been trending extremely negative on Friday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a daily sentiment score of -4.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,640,000 shares, an increase of 5.6% from the January 15th total of 2,500,000 shares. Based on an average daily volume of 586,200 shares, the short-interest ratio is currently 4.5 days. Currently, 8.5% of the company's stock are short sold. View Deciphera Pharmaceuticals' Current Options Chain.

Some companies that are related to Deciphera Pharmaceuticals include Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD) and Reata Pharmaceuticals (RETA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), Viking Therapeutics (VKTX), Exelixis (EXEL), Global Blood Therapeutics (GBT), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (4.65%), New Leaf Venture Partners L.L.C. (4.09%), ArrowMark Colorado Holdings LLC (3.32%), Alliancebernstein L.P. (2.46%), State Street Corp (2.03%) and Farallon Capital Management LLC (1.86%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View Institutional Ownership Trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Point72 Asset Management L.P., Janus Henderson Group PLC, Alliancebernstein L.P., ArrowMark Colorado Holdings LLC, Kornitzer Capital Management Inc. KS, UBS Group AG and Spark Investment Management LLC. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly. View Insider Buying and Selling for Deciphera Pharmaceuticals.

DCPH stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, State Street Corp, Lord Abbett & CO. LLC, Capital World Investors, Farallon Capital Management LLC, Casdin Capital LLC and Pictet Asset Management Ltd.. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $51.15.

Deciphera Pharmaceuticals has a market capitalization of $2.77 billion. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals.

The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/.

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]